ABSI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -49.65%. Absci's return on equity of -50.63% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Absci has a consensus price target of $9.13, signalling upside risk potential of 225.89%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Absci has higher upside potential than NovaBay Pharmaceuticals, analysts believe Absci is more attractive than NovaBay Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Absci's net income of -$29M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Absci's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 68.07x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of -4358.35% compared to Absci's net margin of --. Absci's return on equity of -50.63% beat Internet Patents Corporation's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 225.89%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Absci has higher upside potential than Internet Patents Corporation, analysts believe Absci is more attractive than Internet Patents Corporation.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are larger than Internet Patents Corporation quarterly revenues of --. Absci's net income of -$29M is higher than Internet Patents Corporation's net income of --. Notably, Absci's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 68.07x versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -1366.49%. Absci's return on equity of -50.63% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Absci has a consensus price target of $9.13, signalling upside risk potential of 225.89%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.43 which suggests that it could grow by 69.22%. Given that Absci has higher upside potential than Recursion Pharmaceuticals, analysts believe Absci is more attractive than Recursion Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Absci's net income of -$29M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Absci's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 68.07x versus 23.19x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -4358.35% compared to Absci's net margin of --. Absci's return on equity of -50.63% beat Theriva Biologics's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 225.89%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 832.84%. Given that Theriva Biologics has higher upside potential than Absci, analysts believe Theriva Biologics is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are larger than Theriva Biologics quarterly revenues of --. Absci's net income of -$29M is lower than Theriva Biologics's net income of -$4.4M. Notably, Absci's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 68.07x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.